Wedbush Research Analysts Lower Earnings Estimates for WVE

Key Points

• Wedbush analysts have revised their Q3 2025 earnings per share (EPS) estimate for WAVE Life Sciences from ($0.27) to ($0.31), maintaining an "Outperform" rating with a price target of $18.00.
• WAVE Life Sciences reported Q2 earnings of ($0.31) EPS, missing consensus estimates, with revenues of $8.70 million compared to the forecast of $11.52 million.
• Institutional investors hold 89.73% of WAVE Life Sciences shares, indicating strong institutional interest in the company.

WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Analysts at Wedbush lowered their Q3 2025 earnings estimates for shares of WAVE Life Sciences in a note issued to investors on Wednesday, July 30th. Wedbush analyst Y. Zhong now anticipates that the company will post earnings per share of ($0.31) for the quarter, down from their previous forecast of ($0.27). Wedbush currently has a "Outperform" rating and a $18.00 target price on the stock. The consensus estimate for WAVE Life Sciences' current full-year earnings is ($1.14) per share. Wedbush also issued estimates for WAVE Life Sciences' Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.20) EPS, FY2026 earnings at ($1.08) EPS, FY2027 earnings at ($1.32) EPS, FY2028 earnings at ($0.91) EPS and FY2029 earnings at ($0.67) EPS.

Several other equities analysts have also issued reports on the company. Canaccord Genuity Group initiated coverage on WAVE Life Sciences in a research note on Monday. They issued a "buy" rating and a $19.00 price target on the stock. Wall Street Zen lowered WAVE Life Sciences from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Wells Fargo & Company lowered their target price on WAVE Life Sciences from $24.00 to $21.00 and set an "overweight" rating on the stock in a research report on Thursday, July 31st. Cantor Fitzgerald started coverage on WAVE Life Sciences in a research report on Tuesday, April 29th. They set an "overweight" rating and a $10.00 target price on the stock. Finally, Raymond James Financial started coverage on WAVE Life Sciences in a research note on Wednesday, June 11th. They issued an "outperform" rating and a $14.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and fourteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, WAVE Life Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $20.27.

WAVE Life Sciences Trading Down 4.2%

WVE stock traded down $0.36 during trading on Monday, hitting $8.19. The company had a trading volume of 586,139 shares, compared to its average volume of 1,302,787. The business has a 50-day moving average of $7.38 and a 200-day moving average of $8.26. WAVE Life Sciences has a one year low of $5.04 and a one year high of $16.74. The stock has a market cap of $1.30 billion, a PE ratio of -9.14 and a beta of -0.95.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.02). The business had revenue of $8.70 million during the quarter, compared to analysts' expectations of $11.52 million.

Institutional Trading of WAVE Life Sciences

A number of large investors have recently modified their holdings of WVE. GF Fund Management CO. LTD. acquired a new stake in WAVE Life Sciences in the fourth quarter valued at about $40,000. Quarry LP purchased a new position in WAVE Life Sciences in the fourth quarter valued at about $62,000. Knott David M Jr purchased a new position in WAVE Life Sciences in the first quarter valued at about $81,000. Ascent Group LLC purchased a new position in WAVE Life Sciences in the first quarter valued at about $83,000. Finally, Chicago Partners Investment Group LLC purchased a new position in WAVE Life Sciences in the first quarter valued at about $103,000. Hedge funds and other institutional investors own 89.73% of the company's stock.

Insider Activity at WAVE Life Sciences

In other WAVE Life Sciences news, Director Gregory L. Verdine sold 30,000 shares of the business's stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $6.95, for a total value of $208,500.00. Following the sale, the director owned 282,517 shares of the company's stock, valued at $1,963,493.15. The trade was a 9.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 23.98% of the company's stock.

About WAVE Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.